Olivier Capitain

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes

Most-Cited Works

• → Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial(2021)218 cited
• → Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer(2013)149 cited
• → 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial(2019)126 cited
• → Predictive Factors of Oxaliplatin Neurotoxicity: The Involvement of the Oxalate Outcome Pathway(2007)123 cited
• → Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial(2019)108 cited
• → The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer(2007)98 cited
• → Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study(2012)84 cited
• → TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).(2019)82 cited
• → Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach(2017)78 cited
• → Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients(2016)58 cited